
GENEMEDI
Innovation In Gene Therapy & Biologics


CAR-X™ Solution

For CAR Detection, CAR+ Cell Enrichment, and CAR Lentiviral Engineering



Detect. Enrich. Engineer.

A CAR Detection & Characterization




- **CAR Detection Antibodies (FC)**
  Anti-G4S Linker / Anti-Whitlow (218) Linker / Anti-VHH / Anti-FMC63 mAbs
- **Soluble CAR Detection Kits (ELISA)**
  CD19 / CD20 / HER2 / BCMA / GPC3
- **Immune Cells Characterization Antibodies (FC)**
  CD3 / CD4 / CD8 / CD56 .....
- **Cytokine Detection Kits (ELISA)**
  IL-6 / TNF-α / IFN-γ / IL-2

B CAR+ Cell Enrichment & Assay Development



- **CAR+ Cell Enrichment Beads**
  Anti-G4S Linker / Anti-Whitlow (218) Linker / Anti-VHH Nanobeads
- **Immune Cell Isolation Beads & Kits**
  CD3 / CD4 / CD8 / NK Cells
- **Anti-TAA Antibodies (FC)**
  CD19 / CD123 / GPC3 / HLA-G.....
- **Recombinant Cytokines**
  IL-2 / IL-7 / IL-15 / IL-21.....

C CAR Lentivirus



- **Cargo**
  CD19 CAR, CD20 CAR, HER2 CAR, BCMA CAR, GPC3 CAR
- **Fusogen**
  VSV-G/mutant, Cocal/mutant
- **Binder**
  CD3, CD7



*CAR: Chimeric Antigen Receptor

Table Of Contents

A CAR Detection & Enrichment

01	Flow Cytometry Antibodies: CAR Detection	▸ Product List ▸ Validation Data
02	CAR+ Cell Enrichment Beads	▸ Product List ▸ Validation Data
03	Soluble CAR Detection ELISA Kits	▸ Product List

B Immune Cell Isolation & Detection

01	SOLIDEX®-ISOEx Immune Cells Isolation Beads & Kits	▸ Product List ▸ Validation Data
02	Flow Cytometry Antibodies: Immune Cells Characterization & Functional Assays	▸ Product List ▸ Validation Data
03	Flow Cytometry Antibodies: Anti-TAA / CAR Targets	▸ Product List
04	Cytokine Detection ELISA Kits	▸ Product List
05	Recombinant Cytokines	▸ Product List

C CAR Lentivirus Engineering

01	Good-Validated Premade Lenti-CAR Particles	▸ Product List ▸ Validation Data

A | CAR Detection & Enrichment

1. Flow Cytometry Antibodies: CAR Detection

Anti-G4S Linker / Anti-Whitlow (218) Linker / Anti-VHH / Anti-FMC63 mAbs: PE/FITC/APC/Biotin

Cat.No	Products Name
GMLS-Tag003-Ab01	Anti-G4S Linker monoclonal antibody
GMLS-Tag006-Ab01	Anti-Whitlow (218) Linker monoclonal antibody
GMLS-Tag002-Ab01	Anti-VHH monoclonal antibody
GTU-ADA-FMC63-Ab01~06	Anti-FMC63 monoclonal antibody (anti-idiotype)

2. CAR+ Cell Enrichment Beads

Anti-G4S Linker / Anti-Whitlow (218) Linker / Anti-VHH Nanobeads

Cat.No	Products Name
GMLS-Tag003-Ab01-nanoIMB	SOLIDEX®-ISOEx Anti-G4S Linker Nanobeads
GMLS-Tag006-Ab01-nanoIMB	SOLIDEX®-ISOEx Anti-Whitlow (218) Linker Nanobeads
GMLS-Tag002-Ab01-nanoIMB	SOLIDEX®-ISOEx Anti-VHH Nanobeads
GMLS-Tag003-Ab01-kit	SOLIDEX®-ISOEx Indirect Anti-G4S Linker Isolation Kit (Column-based)
GMLS-Tag003-Ab01-kit-CF	SOLIDEX®-ISOEx Indirect Anti-G4S Linker Isolation Kit (Column-free)
GMLS-Tag006-Ab01-kit	SOLIDEX®-ISOEx Indirect Anti-Whitlow (218) Linker Isolation Kit (Column-based)
GMLS-Tag006-Ab01-kit-CF	SOLIDEX®-ISOEx Indirect Anti-Whitlow (218) Linker Isolation Kit (Column-free)
GMLS-Tag002-Ab01-kit	SOLIDEX®-ISOEx Indirect Anti-VHH Isolation Kit (Column-based)
GMLS-Tag002-Ab01-kit-CF	SOLIDEX®-ISOEx Indirect Anti-VHH Isolation Kit (Column-free)

3. Soluble CAR Detection ELISA Kits

Capture antibody + Biotinylated antigen: CD19 / CD20 / HER2 / BCMA / GPC3

Cat.No	Products Name
GMV-LVc-CD19-ELISA-1	Soluble CD19 CAR Sandwich ELISA Kit
GMV-LVc-CD20-ELISA-1	Soluble CD20 CAR Sandwich ELISA Kit
GMV-LVc-Her2-ELISA-1	Soluble HER2 CAR Sandwich ELISA Kit
GMV-LVc-BCMA-ELISA-1	Soluble BCMA CAR Sandwich ELISA Kit
GMV-LVc-GPC3-ELISA-1	Soluble GPC3 CAR Sandwich ELISA Kit

Validation | CAR Detection Tools

Anti-tag antibodies selectively recognise their cognate CAR surface structures

CAR constructs and antibody target regions




Figure 1. Domain organization of the three CAR constructs tested. Amber marks the (G4S)n linker and the Whitlow 218 spacer; the same designs were packaged into CD19-CAR (G4S, Whitlow 218) and BCMA-CAR (VHH) lentiviral vectors.

Binding test in CAR-expressing Jurkat cells




Figure 2. Binding of the anti-tag mAbs to CAR-expressing Jurkat cells. Each antibody stains only the CAR carrying its cognate structure (98.4-99.8% positive), whereas all mismatched antibody-CAR pairs stay at background. The anti-G4S antibody cannot bind the (G4S)x1 linker.

Validation | CAR Detection Tools

Anti-tag antibodies selectively recognise their cognate CAR surface structures




Figure 3. The same panel in CAR lentivirus (LV)-transduced hPBMCs. The Whitlow 218 CAR-expressing hPBMCs were co-stained with anti-Whitlow 218 and anti-CD3 antibodies, as this vector carries no EGFP reporter. None of these antibodies bound the non-target cells.

Validation | CAR Detection Tools

Anti-G4S Linker / Anti-VHH / Anti-FMC63 mAbs — flow cytometry and affinity

SOLIDEX®-Tag Anti-G4S Linker monoclonal antibody




Figure 1. For detecting CAR-T cells, GeneMedi's Anti-G4S Linker monoclonal antibody exhibits lower background and detection antibody results are closer to specific antigen detection, compared to Company C.

SOLIDEX®-Tag Anti-VHH monoclonal antibody




Figure 2. Anti-VHH monoclonal antibody effectively detects VHH-based anti-Target CAR expression in transfected 293T cells, with greater consistency with the target protein compared to Company G.

SOLIDEX®-Tag Anti-FMC63 monoclonal antibody




Figure 3. GeneMedi's Anti-FMC63 monoclonal antibody is validated to detect simulated samples of CAR-NK infusion in patients.

Validation | CAR+ Cell Enrichment Beads

Magnetic enrichment of CAR+ cells with biotinylated anti-tag antibodies and anti-biotin nanobeads:


Enrichment procedure for CAR+ cells

① Stain CAR+ cells with biotinylated anti-tag mAb → ② Add anti-biotin mAb-2 nanobeads → ③ MACS separation: enriched fraction vs flow-through

Purity: 96.6–97.2% CAR+ | **Apparent recovery: 84.3–95.0%** | **Total labelling time ≈ 20 min**

Figure 1. Procedure for the magnetic separation.

Representative enrichment of CAR+ cells



Mixture of Jurkat-wt: Jurkat-G4S CAR: Jurkat-Whitlow 218 CAR: Jurkat-VHH CAR in 1:1:1:1.


Figure 2. Flow cytometric analysis of the separation of CAR+ cells in a 1:1:1:1 mixture of Jurkat cells containing different CARs. The purity of target cells in the enriched fraction is 96.6-97.2%, while non-target cells pass through unaffected (26.8-36.7%).

Validation | CAR+ Cell Enrichment Beads

Magnetic enrichment of CAR+ cells with biotinylated anti-tag antibodies and anti-biotin nanobeads

Summarized data of CAR+ cell isolation

Antibody	Input proportion	Enriched purity	Apparent recovery
Anti-G4S	**29.1%**	**96.6%**	**94.2%**
Anti-Whitlow 218	**23.1%**	**97.2%**	**84.3%**
Anti-VHH	**23.7%**	**96.8%**	**95.0%**






Figure 3. Purity and recovery of CAR+ cell isolation with anti-G4S, anti-Whitlow 218 and anti-VHH antibodies.

B | Immune Cell Isolation & Detection

1. SOLIDEX®-ISOEx Immune Cells Isolation Beads & Kits

Pan-T / CD4 / CD8 / NK / monocyte: Column-based & Column-free

Cat.No	Products Name
Untouched (Negative Selection) — Column-based	
GM-Pan-T-Cell-iso-kit	SOLIDEX®-ISOEx Untouched Human CD3+ Pan-T Cell Isolation Kit
GM-CD4-T-Cell-iso-kit	SOLIDEX®-ISOEx Untouched Human CD4+ T Cell Isolation Kit
GM-CD8-T-Cell-iso-kit	SOLIDEX®-ISOEx Untouched Human CD8+ T Cell Isolation Kit
GM-NK-Cell-iso-kit	SOLIDEX®-ISOEx Untouched Human NK Cell Isolation Kit
GM-Tg-hg-T23212-iso-kit-1	SOLIDEX®-ISOEx Untouched Human Classical Monocyte Isolation Kit
Untouched (Negative Selection) — Column-free	
GM-Pan-T-Cell-iso-kit-CF	SOLIDEX®-ISOEx Untouched Human CD3+ Pan-T Cell Isolation Kit
GM-CD4-T-Cell-iso-kit-CF	SOLIDEX®-ISOEx Untouched Human CD4+ T Cell Isolation Kit
GM-CD8-T-Cell-iso-kit-CF	SOLIDEX®-ISOEx Untouched Human CD8+ T Cell Isolation Kit
GM-NK-Cell-iso-kit-CF	SOLIDEX®-ISOEx Untouched Human NK Cell Isolation Kit
GM-Tg-hg-T23212-iso-kit-CF-1	SOLIDEX®-ISOEx Untouched Human Classical Monocyte Isolation Kit

2. Flow Cytometry Antibodies: Immune Cells Characterization & Functional Assays

Core phenotype & Functional Assays markers: PE / FITC / APC / Biotin

Marker Category	Marker / Target
T / NK lineage & subsets	CD3E, CD4, CD8, CD56 (NCAM1), CD16, CD45, TCR αβ, TCR γδ
Myeloid & Fc-receptor QC	CD14, CD15, CD66b, CD32 (FcγRII)
Activation & exhaustion	CD25 (IL-2RA), CD69, CD137 (4-1BB), OX40 (CD134), PD-1, TIM-3, LAG-3, TIGIT
Cytotoxicity & function	CD107a (LAMP1), CD63, Granzyme B, Perforin
Cytokine release	IFN-γ, TNF-α
Memory & other lineage	CD45RA, CCR7 (CD197), CD34, CD138

3. Flow Cytometry Antibodies: Anti-TAA / CAR Targets

CAR target markers: PE / FITC / APC / Biotin

Marker Category	Marker / Target
CAR targets — haematological	CD19, CD20 (MS4A1), BCMA (TNFRSF17), CD138 (Syndecan-1), GPRC5D, CD123 (IL3RA), CD33, CLEC12A (CD371), FLT3 (CD135), CD7
CAR targets — solid tumour	GPC3 (Glypican 3), HER2 (ERBB2), PSMA (FOLH1), TMEFF2, B7-H6 (NCR3LG1; haem & solid), EGFR, Claudin 18, ROR1, HLA-G, B7-H3 (CD276), DLL3, SSTR2, EGFR vIII, B7-H4 (VTCN1)

4. Cytokine Detection ELISA Kits

IL-6 / TNF-α / IFN-γ / IL-2: potency and CRS readouts

Immune Cell Association	Cytokine
T / NK Cell-Associated	IL-2, IFN-γ
Myeloid / Monocyte-Associated	IL-6, TNF-α

5. Recombinant Cytokines

Recombinant human cytokines for expansion culture

Cell Type	Cytokine
T Cell-Associated	IL-2, IL-7, IL-15, IL-21
NK Cell-Associated	IL-2, IL-15, IL-18
T / NK Cell-Associated (potentiating)	IL-12, IL-18

Validation | Untouched Isolation (Column-based)

High-Purity NK / Pan-T / CD4⁺ / CD8⁺ T Cell and Monocyte Isolation

SOLIDEX®-ISOEx Untouched Human NK Cell Isolation Kit




Figure 1. CD56+ NK Cell purity increased from an initial 5.67% to 97.7% post-isolation.

SOLIDEX®-ISOEx Untouched Human CD3+ Pan-T Cell Isolation Kit




Figure 2. CD3+ T Cell purity increased from an initial 58.9% to 98.1% post-isolation.

SOLIDEX®-ISOEx Untouched Human CD4+ T Cell Isolation Kit




Figure 3. CD4+ T Cell purity increased from an initial 44.6% to 97.5% post-isolation.

SOLIDEX®-ISOEx Untouched Human CD8+ T Cell Isolation Kit




Figure 4. CD8+ T Cell purity increased from an initial 22.6% to 96.2% post-isolation.

SOLIDEX®-ISOEx Untouched Human Classical Monocyte Isolation Kit




Figure 5. Monocyte purity increased from an initial 21.7% to 96.3% post isolation.

Column-Based Negative Selection

Untouched cells — no antibody or bead left on the target

1 Negative selection

An antibody cocktail binds non-target cells; the wanted cells pass through unlabelled and functionally intact.

2 CAR-X ready

Untouched T / NK cells keep full activation and transduction capacity for CAR-T / CAR-NK manufacturing.

3 High Purity

≥96% for NK, Pan-T, CD4, CD8 and Monocyte with standard magnetic columns.

Validation | Untouched Isolation (Column-free)

High-Purity NK / Pan-T / CD4⁺ / CD8⁺ T Cell and Monocyte Isolation

SOLIDEX®-ISOEx Untouched Human NK Cell Isolation Kit




Figure 1. CD56+ NK Cell purity increased from an initial 19.0% to 94.6% post-isolation.

SOLIDEX®-ISOEx Untouched Human Pan-T Cell Isolation Kit




Figure 2. CD3+ T Cell purity increased from an initial 40.7% to 97.9% post-isolation.

SOLIDEX®-ISOEx Untouched Human CD4+ T Cell Isolation Kit




Figure 3. CD4+ T Cell purity increased from an initial 18.4% to 95.1% post-isolation.

SOLIDEX®-ISOEx Untouched Human CD8+ T Cell Isolation Kit




Figure 4. CD8+ T Cell purity increased from an initial 12.1% to 93.8% post-isolation.

Column-Free Untouched Isolation

No column hardware, fewer steps, faster to cells

1 Faster, fewer steps

Direct in-tube depletion — no column equilibration, washing or elution, so isolation takes less handling time and scales easily.

2 Untouched target cells

No label remains on CD3+, CD4+, CD8+ T or CD56+ NK cells, keeping surface receptors and signalling intact.


3 CAR-X ready

Isolated cells feed straight into CAR lentiviral transduction, expansion and the full CAR-X analytics workflow.


Validation

SOLIDEX®-CDEx Flow Cytometry Antibodies (Naked / PE / APC / FITC / Biotin) on PBMC subsets


Anti-huCD66b




Anti-huCD34




Anti-huCD56




Anti-huCD14




Anti-huCD19




Anti-huCD3




Anti-huCD4



Anti-huCD8



Anti-huCD45



Conclusion


GeneMedi's anti-human CD3, CD4, CD8, CD14, CD19, CD56 (NCAM1), CD45, CD66b (CEACAM8) and CD34 antibodies are validated by flow cytometry for detecting specific PBMC-derived cell types.

Each panel compares the GeneMedi antibody with a reference antibody across a titration series of staining concentrations.


Validation | Flow Cytometry on PBMC Subsets

SOLIDEX®-CDEx Flow Cytometry Antibodies (Naked / PE / APC / FITC / Biotin)


Anti-huCD66b




Anti-huCD34




Anti-huCD56




Anti-huCD14




Anti-huCD19




Anti-huCD3



Anti-huCD4



Anti-huCD8



Cat.No	Product Name
GM-Tg-hg-MP0250-Ab-3	Anti-Human CD66b (CEACAM8) monoclonal antibody
GM-Tg-hg-T66426-Ab-3/4/7/8	Anti-Human CD34 monoclonal antibody
GM-Tg-hg-T86323-Ab-1	Anti-Human CD56 (NCAM1) monoclonal antibody
GM-Tg-hg-T23212-Ab-1	Anti-Human CD14 monoclonal antibody
GM-Tg-hg-T56365-Ab-1	Anti-Human CD19 monoclonal antibody
GM-Tg-hg-T87075-Ab-1	Anti-Human CD3 monoclonal antibody
GM-Tg-hg-T10191-Ab-1/2	Anti-Human CD4 monoclonal antibody
GM-Tg-hg-TA040-Ab-1	Anti-Human CD8 monoclonal antibody
GM-Tg-hg-T43115-Ab-4	Anti-Human CD45 monoclonal antibody

Conclusion: Nine CDEx antibodies detect PBMC-derived subsets with the expected staining pattern; representative plots are shown above.

Validation

SOLIDEX®-CDEx Flow Cytometry Antibodies (Naked / PE / APC / FITC / Biotin) on hPBMC





Figure 1. Flow Cytometry Antibodies are validated to detect PBMC-derived specific cell types by flow cytometry. A–N. Anti-Human CD3/CD3E antibody (A), Anti-Human CD4 antibody (B), Anti-Human CD7 antibody (C), Anti-Human CD8/CD8A antibody (D), Anti-Human CD14 antibody (E), Anti-Human CD16/FCGR3A antibody (F), Anti-Human CD19 antibody (G), Anti-Human CD32/FCGR2B antibody (H), Anti-Human CD33 antibody (I), Anti-Human CD45RA antibody (J), Anti-Human NCAM1 (CD56) antibody (K), Anti-Human CD123/IL3RA antibody (L), Anti-Human TCR alpha-beta antibody (M), Anti-Human TCR gamma-delta antibody (N). Antibodies were stained at 333 ng/mL (PE conjugate) on hPBMC; percentages indicate gated populations of total events.

C | CAR Lentivirus

Good Validated Premade Lenti-CAR Particles

Component	Configuration
Cargo	CD19 CAR, CD20 CAR, HER2 CAR, BCMA CAR, GPC3 CAR
Fusogen	VSV-G/mutant, Cocal/mutant
Binder	CD3, CD7

CAR-X Good-Validated Premade Lenti-CAR Particles



	Name of GMLv-CAR	CAR Structure	Cassette	G4S Linker	FMC63	EGFP
1	Lenti-CAR-CD19-S1-EGFP-Puro	CD19 SCFV (FMC63)-CD8-4-1BB-CD3ζ-EGFP-Puromycin;	LV-EF1-CAR-P2A-EGFP-T2A-Puromycinmycin	Y	Y	Y
2	Lenti-CAR-CD19-S2-EGFP-Puro	CD19 SCFV (FMC63)-CD28-CD3ζ-EGFP-Puromycin;	LV-EF1-CAR-P2A-EGFP-T2A-Puromycin	N	Y	Y
3	Lenti-CAR-CD19-S3-EGFP-Puro	CD19 SCFV (FMC63)-CD8-CD28-4-1BB-CD3ζ-EGFP-Puromycin,	LV-EF1-CAR-P2A-EGFP-T2A-Puromycin	Y	Y	Y
4	GMLV-EF1-MCS-P2A-EGFP-T2A-PURO	Null	LV-EF1-MCS-P2A-EGFP-T2A-Puromycin	N	N	Y
5	Lenti-CAR-CD19-S1-Puro	CD19 SCFV (FMC63)-CD8-4-1BB-CD3ζ-Puromycin;	LV-EF1-CAR-P2A-Puromycin	Y	Y	N
6	Lenti-CAR-CD19-S2-Puro	CD19 SCFV (FMC63)-CD28-CD3ζ-Puromycin;	LV-EF1-CAR-P2A-Puromycin	N	Y	N
7	Lenti-CAR-CD19-S3-Puro	CD19 SCFV (FMC63)-CD8-CD28-4-1BB-CD3ζ-Puromycin,	LV-EF1-CAR-P2A-Puromycin	Y	Y	N
8	GMLV-EF1-MCS-P2A-Puro	Null	LV-EF1-MCS-P2A-Puromycin	N	N	N
9	Blank	Null	Null	N	N	N

Figure 1. GM-Lenti-CAR Lentivirus represent a great performence in CAR-expression

Cat.No	Products Name	Description
GMV-LVc-CD19	CD19 CAR Lentivirus	Our CD19 CAR Lentivirus is specifically designed to target CD19, a critical marker of B-cell malignancies. This vector is a cornerstone in the treatment of various leukemias and lymphomas, offering a beacon of hope for patients battling these cancers.
GMV-LVc-CD20	CD20 CAR Lentivirus	Targeting CD20-positive malignancies, our CD20 CAR Lentivirus is engineered to facilitate groundbreaking treatments against conditions such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, showcasing our commitment to combating hematological cancers.
GMV-LVc-HER2	HER2 CAR Lentivirus	Our HER2 CAR Lentivirus targets the HER2 protein, offering a strategic approach to treating HER2-positive breast cancer. This vector embodies our dedication to advancing precision medicine and providing targeted therapies for patients with breast cancer.
GMV-LVc-BCMA	BCMA CAR Lentivirus	Focused on BCMA, a protein implicated in the pathogenesis of multiple myeloma, our BCMA CAR Lentivirus underscores our commitment to addressing this challenging condition with targeted therapeutic strategies.
GMV-LVc-GPC3	GPC3 CAR Lentivirus	By targeting GPC3, associated with hepatocellular carcinoma, our GPC3 CAR Lentivirus reflects our dedication to pioneering treatments for hard-to-treat cancers, emphasizing our innovative approach to cancer therapy.

About GeneMedi

GeneMedi was founded in 2018 by a team of interdisciplinary experts in drug discovery, CMC process development, computational biology, and materials chemistry. GeneMedi is dedicated to empowering cell and gene therapy (CGT) development through high-efficiency purification and rigorous quality control solutions.

GENEMEDI
Innovation In Gene Therapy & Biologics

Our mission: Innovate biologics to empower gene and cell therapy. GeneMedi combines world-class technology platforms with a rigorous quality management system. GeneMedi delivers reliable, high-performance solutions to global clients, helping to accelerate drug R&D.

SOLIDEX®-ISOEx Technical Platforms

GM-ExBeads™
Microsphere Engineering & Modification

Features full-scale bead synthesis capabilities. Utilizing proprietary surface chemistry, it achieves oriented ligand arrangement and steric optimization to effectively eliminate non-specific aggregation.

GM-LIBRA™
AI-Driven Ligand Evolution

Leverages AI for precise epitope prediction and binding analysis. By identifying optimal antibodies, it significantly enhances capture efficiency while minimizing non-specific adsorption.

GM-ExImmune
Integrated Immune Cell Verification

Strictly validates the viability and functionality of sorted cells. It provides panoramic immunophenotyping analysis to meet the specific demands of advanced immunotherapies, including T/NK Cell Engagers.

GVC
(GM Vector Core)

A Quality-by-Design (QbD) platform dedicated to viral vector process development. It delivers tailored, high-quality production strategies for diverse, novel AAV serotypes, lentiviruses with engineered envelopes, and adenoviruses with modified fibers, establishing robust and scalable processes to support advanced research and downstream manufacturing.

Core Advantages

International Quality Management System

GeneMedi strictly follows ISO 9001 and ISO 13485 standards and implemented a digital quality traceability system to ensure exceptional product quality.

Professional Team

Our team of 60+ cross-disciplinary experts brings over 10 years of average industry experience and in-depth knowledge of GCT and antibody development requirements.

Technology Innovation

AI-driven product design platform is integrated with a million-level biological big data database to speed up product iteration and enhance performance.

Request product sample

➢ Scan the QR Code